Latest Press Releases

Challenges in Recruiting Disability Support Workers

In order to help people with impairments live independent, satisfying lives, the disability support industry is essential. However, the lack of skilled and motivated disability assistance workers is a major issue facing the sector. Both people ...

Teledyne e2v Announces New High-speed Sensor with Extended Sensitivity in NIR Wavelengths

GRENOBLE, France, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, introduces Lince5M™ NIR , a state-of-the-art high-speed CMOS image sensor. Leveraging ...

Philips Publishes its Annual Report 2024

February 21, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today published its Annual Report 2024. Philips’ Annual Report 2024 will be on the agenda of the Annual General ...

Yaqrit Strengthens Board and Senior Management Ahead of Multi-prong Clinical Push in Advanced Liver Disease

Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 ...

Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights

February 21, 2025 Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Mass ...

Study Finds Digital Peer Support Reduces Need for Therapy Sessions, Enhances Access, and Lowers Costs

PR Newswire BERKELEY, Calif., Feb. 25, 2025 A new study published in JMIR Human Factors highlights the potential of digital peer support in addressing the growing mental health crisis in the United States. BERKELEY, Calif., Feb. 25, 2025 ...

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

PR Newswire VICTORIA, BC, Feb. 25, 2025 VICTORIA, BC, Feb. 25, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company specializing in precision local ...

National survey reveals low understanding of shingles risk factors and lack of concern among those at increased risk

Canada NewsWire MISSISSAUGA, ON, Feb. 25, 2025 MISSISSAUGA, ON, Feb. 25, 2025 /CNW/ - A new national survey of Canadian adults reveals significant gaps in understanding of shingles risk factors and a lack of concern among those most at risk ...

The Tooth Fairy is on a budget

PR Newswire CHICAGO, Feb. 25, 2025 Average value of a lost tooth drops for second consecutive year CHICAGO, Feb. 25, 2025 /PRNewswire/ -- Even the Tooth Fairy sticks to a budget. New findings from the Delta Dental 2025 Original ...

It's Not Just Hot Flashes: Flo Study Reveals Early Psychological Impact of Perimenopause

PR Newswire LONDON, Feb. 25, 2025 Two-thirds of women aged 36-40 experience moderate to severe symptoms, yet wait decades before seeking treatment LONDON, Feb. 25, 2025 /PRNewswire/ -- Flo, the #1 women's health app used by 75 million ...

bioMérieux Receives Health Canada Approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

Canada NewsWire MONTREAL, Feb. 25, 2025 MONTREAL, Feb. 25, 2025 /CNW/ - bioMérieux, a world leader in the field of in vitro diagnostics, has achieved a significant milestone with the Health Canada approval of the BIOFIRE® SPOTFIRE® ...

MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment

PR Newswire SHANGHAI, Feb. 25, 2025 SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced significant progress in its global multicenter Phase III clinical trial evaluating ...

Challenges in Recruiting Disability Support Workers

In order to help people with impairments live independent, satisfying lives, the disability support industry is essential. However, the lack of skilled and motivated disability assistance workers is a major issue facing the sector. Both people ...

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

PR Newswire SHANGHAI, Feb. 25, 2025 SHANGHAI, Feb. 25, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines, today reported ...

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

PR Newswire SHANGHAI, Feb. 23, 2025 SHANGHAI, Feb. 23, 2025 /PRNewswire/ -- BioCity Biopharma (BioCity) announced that its selective endothelin receptor type A (ETA) antagonist, SC0062, met the 12-week primary endpoint of a reduction in ...

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

PR Newswire SUZHOU, China, Feb. 24, 2025 SUZHOU, China, Feb. 24, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer ...

HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to Exhibit Remarkable Growth at a CAGR of 9.2% by 2034 | DelveInsight

PR Newswire LAS VEGAS, Feb. 24, 2025 The HPV16+ HNSCC market is experiencing robust growth, driven by increasing awareness of HPV-related cancers and the rising incidence of oropharyngeal cancers. The development of immunotherapies and ...

Improving access to mental health services for Black Canadians

Canada NewsWire EDMONTON, AB, Feb. 24, 2025 EDMONTON, AB, Feb. 24, 2025 /CNW/ - Black Canadians continue to face significant barriers to accessing mental health services and supports, including cost of care, a history of systemic racism and ...

Omalizumab Is Superior to Oral Immunotherapy in Multi-Food Allergy Treatment

PR Newswire MILWAUKEE, Feb. 24, 2025 Food allergic patients have better outcomes with omalizumab than oral immunotherapy MILWAUKEE, Feb. 24, 2025 /PRNewswire-PRWeb/ -- Food allergy treatment with omalizumab resulted in better outcomes ...

Initiation of ReDS-SAFE HF II Trial for Advancing Heart Failure Management

PR Newswire BOSTON, Feb. 24, 2025 BOSTON, Feb. 24, 2025 /PRNewswire/ -- At the THT conference, Dr. Jesus Alvarez-Garcia, MD, PhD, head of Advanced Heart Failure Unit at Ramón y Cajal Hospital in Madrid, announced the launch of ReDS-SAFE HF ...

Curai Health Provides Virtual Care for UMass Chan Medical School's NIH-Funded "STOP COVID-19" Study

PR Newswire WASHINGTON, Feb. 24, 2025 The study examines the use and efficacy of at-home COVID-19 testing. WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- UMass Chan Medical School is partnering with Curai Health to provide virtual care to ...

Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's

PR Newswire GALWAY, Ireland, Feb. 24, 2025 New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, ...

Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment

PR Newswire LOUISVILLE, Colo., Feb. 24, 2025 LOUISVILLE, Colo., Feb. 24, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a market leader in hemp extract wellness products, ...

Sterotherapeutics, Announces Initiation of a Phase 2 Clinical Trial for Patients with Cushing's Syndrome

PR Newswire DOYLESTOWN, Pa., Feb. 24, 2025 DOYLESTOWN, Pa., Feb. 24, 2025 /PRNewswire/ -- Sterotherapeutics, a leading biopharmaceutical company dedicated to advancing innovative therapies, is announcing the launch of a Phase 2 clinical ...

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

PR Newswire SAN JOSE, Calif., Feb. 24, 2025 SAN JOSE, Calif., Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

PR Newswire STATEN ISLAND, N.Y., Feb. 24, 2025 STATEN ISLAND, N.Y., Feb. 24, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small ...

DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

PR Newswire LITTLETON, Colo., Feb. 24, 2025 DeFloria plans to initiate a Phase 2 clinical trial by mid-year 2025 LITTLETON, Colo., Feb. 24, 2025 /PRNewswire/ -- DeFloria, Inc., a collaboration between Ajna BioSciences PBC and Charlotte's ...

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

PR Newswire BURLINGTON, N.C., Feb. 24, 2025 Labcorp® Plasma CompleteTM offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw BURLINGTON, N.C., Feb. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: ...

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

PR Newswire SAN FRANCISCO and NEW YORK, Feb. 24, 2025 -- TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) and ...

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

PR Newswire WASHINGTON, Feb. 24, 2025 WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for ...

Unravelling the infection enigma: Jean-Laurent Casanova's pioneering genetic discoveries earn him the 2025 Novo Nordisk Prize

PR Newswire COPENHAGEN, Denmark, Feb. 24, 2025 COPENHAGEN, Denmark, Feb. 24, 2025 /PRNewswire/ -- For decades, scientists believed that infections were determined solely by viruses and bacteria. But Professor Jean-Laurent Casanova's ...

Let doctors practise where they are needed: CMA

Canada NewsWire OTTAWA, ON, Feb. 24, 2025 OTTAWA, ON, Feb. 24, 2025 /CNW/ - As Canadian governments seek to break down internal trade barriers between provinces and territories, the Canadian Medical Association (CMA) urges policymakers to ...

Pearson Professional Center opens in Lahore, Pakistan to expand access to high-stakes testing

PR Newswire BLOOMINGTON, Minn., Feb. 24, 2025 Pearson VUE, the global leader in computer-based professional certification and licensure exam delivery, today announced the opening of its newest company-owned test center for high-stakes ...

Vantage Foundation Brings Hope and Support to Patients at National Burn Hospital, Hanoi

PR Newswire HANOI, Vietnam, Feb. 24, 2025 HANOI, Vietnam, Feb. 24, 2025 /PRNewswire/ -- Vantage Foundation proudly announces its partnership with National Burn Hospital Le Huu Trac in Hanoi, a leading medical facility specialising in burn ...

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

PR Newswire ZURICH, Feb. 24, 2025 ZURICH, Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous ...

Latest Press Releases

Premium Press Releases »

Challenges in Recruiting Disability Support Workers

Teledyne e2v Announces New High-speed Sensor with Extended Sensitivity in NIR Wavelengths

Philips Publishes its Annual Report 2024

Yaqrit Strengthens Board and Senior Management Ahead of Multi-prong Clinical Push in Advanced Liver Disease

Philips and Mass General Brigham announce collaboration to improve patient care with live AI-powered insights

Press Releases »

Study Finds Digital Peer Support Reduces Need for Therapy Sessions, Enhances Access, and Lowers Costs

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

National survey reveals low understanding of shingles risk factors and lack of concern among those at increased risk

The Tooth Fairy is on a budget

It's Not Just Hot Flashes: Flo Study Reveals Early Psychological Impact of Perimenopause

bioMérieux Receives Health Canada Approval for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel

MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment

Challenges in Recruiting Disability Support Workers

YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)

BioCity Announces its selective Endothelin Type-A Receptor Antagonist, SC0062, Met the Primary Endpoint in Diabetic Kidney Disease (DKD) in a Phase 2 trial (2-SUCCEED)

CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA

HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to Exhibit Remarkable Growth at a CAGR of 9.2% by 2034 | DelveInsight

Improving access to mental health services for Black Canadians

Omalizumab Is Superior to Oral Immunotherapy in Multi-Food Allergy Treatment

Initiation of ReDS-SAFE HF II Trial for Advancing Heart Failure Management

Curai Health Provides Virtual Care for UMass Chan Medical School's NIH-Funded "STOP COVID-19" Study

Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's

Charlotte's Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment

Sterotherapeutics, Announces Initiation of a Phase 2 Clinical Trial for Patients with Cushing's Syndrome

Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD)

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

Unravelling the infection enigma: Jean-Laurent Casanova's pioneering genetic discoveries earn him the 2025 Novo Nordisk Prize

Let doctors practise where they are needed: CMA

Pearson Professional Center opens in Lahore, Pakistan to expand access to high-stakes testing

Vantage Foundation Brings Hope and Support to Patients at National Burn Hospital, Hanoi

The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)

Medindia Newsletters